GLP1R and type 2 diabetes mellitus: The first major trial of cardiovascular outcomes in GLP-1 receptor agonists was ELIXA (Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome), where lixisenatide was noninferior compared to placebo in the effect on 3-point MACE (composed of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) [76].